Ibogaine; authorize MSDH to select a consortium to conduct a drug development clinical trial to secure FDA's approval of.
(S) Died In Committee
Email me when SB 2561 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track SB 2561. By continuing you agree to the Terms and Privacy Policy.
Summary
The bill would let Mississippi’s Department of Health choose a partnership of a drug developer, a university and a hospital to conduct a clinical trial of ibogaine for opioid and other substance‑use disorders. The consortium would receive state funding only after matching non‑state money, file an IND with the FDA, and try to obtain breakthrough‑therapy status. The measure failed and never left the Senate committee.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about SB 2561
3 free questions a day, no accountHistory
- Died In Committee
- Referred To Public Health and Welfare
Sponsors
- Harkins · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when SB 2561 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track SB 2561 freeOr ask your AI assistant about SB 2561 directly:
Add to Claude, ChatGPT or Cursor